Nicotinamide Riboside Protects Against NASH: Preclinical Findings

Synopsis In a rat model of NASH driven by type 2 diabetes and an obesogenic diet, activating SIRT2 with nicotinamide riboside (NR) improved blood sugar, insulin resistance, and glucose tolerance, ...

Nicotinamide Riboside Reduces Liver Inflammation in Alcoholic Liver Disease: Preclinical Findings

Synopsis Alcoholic liver disease (ALD) is a serious liver condition caused by excessive alcohol and has few effective nutritional treatments. Researchers found that brown fat cells release a prote...

Nicotinamide Riboside Protects Against Doxorubicin-Induced Liver and Kidney Toxicity: Preclinical Findings

Synopsis Doxorubicin (DOX) is a powerful chemotherapy drug, but its use is limited because it causes serious liver and kidney toxicity through ferroptosis, an iron-dependent form of cell death dri...

NMN and NR Improve Lipid Metabolism but Promote Atherosclerosis in ApoE-Knockout Mice: Preclinical Findings

Synopsis Supplementation with nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) raised NAD+ levels and produced clear metabolic benefits in mice, including reduced body weight, lowe...

Roseburia hominis and Nicotinamide Riboside Combat Obesity: Preclinical Findings

Synopsis The gut bacterium Roseburia hominis was found to be depleted in obese individuals and negatively correlated with BMI and serum triglycerides. In high-fat diet–fed mice, supplementation wi...

Nicotinamide Riboside Protects Liver Cells from Palmitate-Induced Damage: Preclinical Findings

Synopsis This study examined how excessive fat buildup in liver cells (hepatic lipotoxicity) contributes to liver damage, a key factor in metabolic liver diseases. Researchers found that exposure ...

Nicotinamide Riboside Protects Liver Immune Cells from Alcohol-Induced Damage: Preclinical Findings

SynopsisAlcohol-related liver disease (ALD) is linked to mitochondrial dysfunction and impaired energy metabolism. This study examined how ethanol damages Kupffer cells, the liver's resident immune...

Nicotinamide Riboside Improves Fructose-Induced Lipid Metabolism Disorders: Preclinical Findings

Synopsis This study examined how nicotinamide riboside (NR), a vitamin B3–derived NAD+ booster, protects against fat metabolism disorders caused by high fructose intake. Mice given a 20% fructose ...

Nicotinamide Riboside Restores NAD+ and Reduces Fatty Liver Damage: Preclinical Findings

Synopsis Palmitic acid, the most common saturated fat in the blood, can cause liver inflammation, fat accumulation (steatosis), and cellular damage. This study explored how such fatty acids disrup...

Therapeutic Effects of Nicotinamide Riboside and NMN on Nonalcoholic Fatty Liver Disease (NAFLD): Preclinical Findings

Synopsis This study explored how nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN)—two vitamin B3–derived NAD+ precursors known for their anti-aging and metabolic benefits—affect th...

Nicotinamide Riboside Prevents Nicotine and Coca-Cola™-Induced Fatty Liver: Preclinical Findings

Synopsis Both nicotine—found in cigarettes and e-cigarettes—and high-fructose corn syrup (HFCS)—a sweetener in many soft drinks—are known to harm liver health. This study tested whether combining ...

Comparative Evaluation of Four NAD+ Precursors in Preventing High-Glucose-Induced Hepatocyte Damage: Preclinical Findings

Synopsis Boosting NAD+ levels is known to protect the liver from metabolic stress, but the effectiveness of different NAD+ precursors—nicotinic acid (NA), niacinamide (NAM), nicotinamide riboside ...

Nicotinamide Riboside Attenuates NASH Progression: Preclinical Findings

Synopsis Non-alcoholic steatohepatitis (NASH) is a severe form of fatty liver disease driven by oxidative stress and inflammation. This study investigated whether increasing NADPH, a key molecule ...

Nicotinamide Riboside Protects Against Fat-Induced Liver Damage: Preclinical Findings

Synopsis This study explored how palmitate, a common saturated fat found in the bloodstream, contributes to fatty liver disease by altering cell metabolism. Researchers found that palmitate activa...

Nicotinamide Riboside Slows Liver Cancer Growth and Metastasis: Preclinical Findings

SynopsisNicotinamide adenine dinucleotide (NAD+) metabolism has emerged as a target in cancer treatment. This study evaluated the effects of nicotinamide riboside (NR), a NAD+ precursor, on hepatoc...

Nicotinamide Riboside Corrects Metabolic Imbalances and Mitochondrial Dysfunction in Citrin Deficiency: Preclinical Findings

SynopsisCitrin deficiency (CD) is a genetic metabolic disorder caused by loss of the mitochondrial transporter CITRIN, which plays a role in the urea cycle and malate–aspartate shuttle. Patients wi...

Nicotinamide Riboside and Calorie Restriction Improve Gut Microbiota and Reduce Liver Fat and Inflammation: Preclinical Findings

SynopsisMetabolic dysfunction–related fatty liver disease currently has no specific therapy. This study tested nicotinamide riboside (NR) and dietary restriction (DR) in rats with diet-induced obes...

Nicotinamide Riboside and Pterostilbene Reduce Liver Inflammation in NAFLD: Clinical Findings

Objectives To determine the effects of nicotinamide riboside and pterostilbene (NRPT) supplementation on liver fat in adults with non-alcoholic fatty liver disease (NAFLD). Journal Hepatology Key ...

Nicotinamide Riboside and Metabolic Cofactors Improve Gut Health in Fatty Liver Disease: Preclinical Findings

SynopsisThe gut barrier controls what passes into the body and protects organs like the liver. An unhealthy diet and lifestyle cause gut microbiome imbalances (dysbiosis) and gut barrier damage, wh...

Nicotinamide Riboside Prevents Liver Injury and Restores Mitochondrial Function: Preclinical Findings

SynopsisNAMPT is an enzyme that helps make NAD+. Since low liver NAD+ is linked to fatty liver disease, scientists removed NAMPT specifically from liver cells in mice to see the effect. These mice ...